Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Benjamin Goldstein

Internal Medicine Saint Louis, MO Medical Doctor

NPI 1811919228 CMS profile 82412

8888 Ladue Rd Ste 210, Saint Louis, MO 63124

Open in the dashboard

General payments

$5,097

338 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Benjamin Goldstein of Saint Louis, MO is reported in the CMS Open Payments database as having received $5,097 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $86 4
2023 General $159 8
2022 General $1,813 113
2021 General $1,471 103
2020 General $589 41
2019 General $979 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Goldstein
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Benjamin Goldstein were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Benjamin Goldstein Internal Medicine median Middle half National median
2019 $979 $159 $48–$570 $163
2020 $589 $119 $33–$402 $114
2021 $1,471 $135 $37–$521 $132
2022 $1,813 $141 $42–$496 $149
2023 $159 $149 $45–$519 $160
2024 $86 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lilly USA, LLC $732 51 payments
  2. AbbVie, Inc. $707 39 payments
  3. Novo Nordisk Inc $652 45 payments
  4. Pfizer Inc. $367 25 payments
  5. E.R. Squibb & Sons, L.L.C. $306 20 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $232 18 payments
  7. Janssen Pharmaceuticals, Inc $221 14 payments
  8. Amarin Pharma Inc. $186 15 payments
  9. Eisai Inc. $179 13 payments
  10. Merck Sharp & Dohme Corporation $165 11 payments
  11. Other $1,349 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,079 336 payments
  2. Education $18 2 payments
Products named General payments · program years 2019–2024
  1. Ozempic $455 32 payments
  2. NURTEC ODT $357 25 payments
  3. JARDIANCE $355 23 payments
  4. VRAYLAR $352 21 payments
  5. RYBELSUS $330 23 payments
  6. ELIQUIS $306 20 payments
  7. TRULICITY $295 21 payments
  8. UBRELVY $253 14 payments
  9. XARELTO $221 14 payments
  10. Vascepa $186 15 payments
  11. Other $3,019 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record